Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Cyclosporin for refractory ulcerative colitis

C G Loftus¹, E V Loftus, W J Sandborn

¹Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA.

|January 14, 2003

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.

Digestive diseases and sciences·2024

Same author

Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Authors' reply.

Alimentary pharmacology & therapeutics·2018

Same author

An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease.

Alimentary pharmacology & therapeutics·2018

Same author

Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease.

Alimentary pharmacology & therapeutics·2018

Same author

Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.

Alimentary pharmacology & therapeutics·2018

Same author

Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.

Alimentary pharmacology & therapeutics·2018